The Brian Loggie Story: A Closer Look at Mesothelioma and Creighton University

Introduction

Welcome to a deep dive into Brian Loggie’s journey with mesothelioma, and how his experience ultimately changed the landscape of mesothelioma treatment and research at Creighton University. This is an intricate account of an individual’s specific experience, but it sheds light on a condition that affects thousands of people worldwide. In this article, we’ll explore Loggie’s path, the history of mesothelioma, and how Creighton University has emerged as a leader in mesothelioma research.

Mesothelioma is a cancer that affects the lining of the lungs, stomach, or heart. It is caused primarily by exposure to asbestos, a mineral fiber that was commonly used in construction, insulation, and manufacturing until it was banned for most uses in the US in the 1970s. Mesothelioma is an aggressive disease, and there is currently no cure. Given the long latency period between exposure to asbestos and the onset of symptoms, many cases of mesothelioma are only diagnosed after the disease has progressed to a late stage.

The Beginning of Brian Loggie’s Mesothelioma Journey

In 2010, Brian Loggie, a surgical oncologist, was diagnosed with mesothelioma, despite having no history of asbestos exposure. Loggie was the Chair of the Department of Surgery at Creighton University School of Medicine, and his diagnosis was a catalyst for change in mesothelioma research at the university. His case was unique because of his medical background and the fact that he was diagnosed without any known risk factors.

Loggie underwent surgery, chemotherapy, and radiation treatment, but his mesothelioma recurred. He decided to pursue immunotherapy, a relatively new field of cancer treatment that harnesses the patient’s own immune system to fight cancer cells. After much research and consultation with experts, Loggie began taking a combination of two immunotherapy drugs. Within weeks, his tumors began to shrink, and his health dramatically improved.

The Impact of Loggie’s Mesothelioma on Creighton University

Loggie’s experience with mesothelioma and his successful treatment with immunotherapy has prompted Creighton University to become a leader in mesothelioma research. The school has developed a multidisciplinary team of experts and established a clinical trial program that is focused on testing new treatments for mesothelioma. Creighton’s mesothelioma program is one of only a handful of such programs in the country, and it is uniquely positioned to make groundbreaking discoveries in mesothelioma treatment and care.

Brian Loggie and Creighton University Mesothelioma Details

Details	Information
Brian Loggie’s Diagnosis	Mesothelioma
Brian Loggie’s Treatment	Surgery, chemotherapy, radiation, and immunotherapy
Brian Loggie’s Immunotherapy Drugs	Ipilimumab and Nivolumab
Creighton University’s Mesothelioma Program Details	Multidisciplinary team, clinical trial program, research focus

FAQs

What are the risk factors for mesothelioma?

Exposure to asbestos is the primary risk factor for mesothelioma. Other risk factors include exposure to other natural minerals such as erionite, family history of mesothelioma, and radiation exposure.

What are the symptoms of mesothelioma?

The symptoms of mesothelioma vary depending on the location of the cancer, but common symptoms include chest pain, shortness of breath, abdominal pain, and weight loss.

How is mesothelioma diagnosed?

Mesothelioma is usually diagnosed through imaging tests such as X-rays, CT scans, and MRIs, followed by a biopsy or a fluid analysis.

What is immunotherapy?

Immunotherapy is a type of cancer treatment that uses the patient’s own immune system to fight cancer cells. It can involve the use of drugs, vaccines, or other methods to stimulate the immune system and target cancer cells.

What is Creighton University’s mesothelioma program?

Creighton’s mesothelioma program is a multidisciplinary team of experts that is focused on developing new treatments for mesothelioma. The program includes a clinical trial program and a research focus.

What is the prognosis for mesothelioma?

The prognosis for mesothelioma is generally poor. The average life expectancy after diagnosis is around 12 to 21 months, although some patients may live longer with aggressive treatment.

Can mesothelioma be prevented?

The best way to prevent mesothelioma is to avoid exposure to asbestos. This can include wearing protective gear and following safety regulations in workplaces where asbestos is present.

How common is mesothelioma?

Mesothelioma is a relatively rare cancer, with around 3,000 new cases diagnosed in the US each year. It is more common in men than women and typically affects people over the age of 65.

What is the history of mesothelioma?

Mesothelioma was first identified as a distinct disease in the early 20th century, but it wasn’t until the mid-20th century that the link between asbestos exposure and mesothelioma was established. Asbestos use peaked in the US in the 1970s and has since declined, but mesothelioma cases continue to be diagnosed due to the long latency period between exposure and onset of symptoms.

What is the role of surgery in mesothelioma treatment?

Surgery can be used to remove mesothelioma tumors or to relieve symptoms such as pain and breathing difficulties. However, surgery alone is not usually curative, and it is often combined with other treatments such as chemotherapy and radiation.

What is chemotherapy?

Chemotherapy is a type of cancer treatment that uses drugs to target and kill cancer cells. The drugs can be administered orally or through intravenous infusion.

What is radiation therapy?

radiation therapy uses high-energy radiation to target and kill cancer cells. It can be administered externally or internally and can be used in combination with other treatments such as chemotherapy and surgery.

What are clinical trials?

Clinical trials are research studies that test new treatments or drugs to see if they are safe and effective. Clinical trials can involve patients with mesothelioma who have exhausted standard treatment options.

How can I support mesothelioma research?

You can support mesothelioma research by donating to organizations that fund research, volunteering for clinical trials, and spreading awareness about mesothelioma and its risk factors.

Conclusion

Brian Loggie’s experience with mesothelioma has provided a unique perspective on a disease that affects millions of people worldwide. His treatment with immunotherapy has opened up new avenues for mesothelioma research and has prompted Creighton University to establish itself as a leader in the field. While mesothelioma is still a devastating disease, there is hope that new treatments will continue to emerge and that one day, a cure may be found. By supporting mesothelioma research, we can help to make that hope a reality.

If you or someone you know has been diagnosed with mesothelioma, it’s important to seek out expert medical care and explore all treatment options. With the right care and a supportive community, even a diagnosis of mesothelioma can be faced with hope and resilience.

Closing Disclaimer

This article is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider with any questions you may have about your health or a medical condition.